Agenda

Session I Introduction

Seth A. Wander, MD, PhD

‍

Molecular Residual Disease in Early ER+ Breast Cancer

Arielle J. Medford, MD

‍

Optimizing Targeted Therapy for High Risk Early Stage HR+ Breast Cancer

Claudine Isaacs, MD, FRCPC

‍

Leveraging Molecular Tools to Guide Treatment Planning in HR+ Early Breast Cancer

Stephanie L. Graff, MD, FACP, FASCO

‍

Focused Learning Session:

Oral SERDs: New Advances in the Treatment of Breast Cancer

Seth A. Wander, MD, PhD

Supported by Stemline Therapeutics, Inc.

‍